Showing 51-60 of 1037 results for "".
Social Media Pearls and Pitfalls
https://practicaldermatology.com/topics/practice-management/social-media-pearls-and-pitfalls/18917/Despite offering new opportunities to reach patients, social media platforms also introduce a number of potential pitfalls for physicians. In this edition of Derm Insider, host Neal Bhatia discusses the complex spectrum of social media with guests Abel Torres, MD, Mark Kaufmann, MD, and Nicole DeyamDermatologists Push Back on Wall Street Journal Characterization
https://practicaldermatology.com/issues/january-february-2025/dermatologists-push-back-on-wsj-characterization/32900/Four-day workweeks, double the salary of some colleagues and no emails at night—those were the reasons a Wall Street Journal article concluded that medical residency applications for dermatology slots are up 50% over the past 5 years. Practical Dermatology reached out to dermatologists to get theirEyes Have It: Bloodless Blephs and More
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/eyes-have-it-bloodless-blephs-and-more/18728/Demand for treatments around the eye continue to grow; patients want big results but little downtime. Dr. Niamtu discusses his "bloodless bleph" and other uses for fillers and toxins.DermWireTV: Allē Launches; Arazlo Cleared; BTL Files Suit
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-alle-launches-arazlo-cleared-btl-files-suit/19714/More than 10 Years and 6 million members later, the Brilliant Distinctions program is being relaunched with a new name and a new app: Allē. Arazlo Lotion 0.045%, the first lotion formulation of tazarotene, is now FDA approved for the topical treatment of acne vulgaris in patients nine years of age aEczema Discovery; Ortho Dermatologics, Revision, Alastin Product Launches
https://practicaldermatology.com/topics/practice-management/dermwiretv-eczema-discovery-ortho-dermatologics-revision-alastin-product-launches/18353/Regeneron revealed that Dupixent generated sales of $120M within the first nine months of launch. Researchers have identified a possible treatment for moderate-to-severe atopic dermatitis: IL-22 blockade. Product launches or updates from Revision Skincare, Alastin Skincare, Ortho Dermatologics, andThe Invasion of the Picoseconds
https://practicaldermatology.com/topics/practice-management/the-invasion-of-the-picoseconds/20763/Pico devices are finding their niche, with expanded applications that may make them more attractive for practices.AAD Leaders Discuss New Goals and Initiatives
https://practicaldermatology.com/series/dermwire-tv/aad-leaders-discuss-new-goals-and-initiatives/33154/In this week's DermwireTV, leaders of the American Academy of Dermatology (AAD) discuss the key issues facing the specialty; a new study examines nicotinamide exposure and the risk of major adverse cardiovascular events; and in our C-Suite Chats segment, we hear from an Executive Director at TakePhysician Spotlight: Vishal Anil Patel, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-vishal-anil-patel-md/23899/Game-changing Suturing Techniques
https://practicaldermatology.com/topics/skin-cancer-photoprotection/game-changing-suturing-techniques/20464/Implement these buried suture techniques for better outcomes.Case Report: Henoch-Schönlein Purpura in an Adult; Resident Salary Report
https://practicaldermatology.com/youngmd-connect/resident-resource-center/case-report-henoch-schnlein-purpura-in-an-adult-resident-salary-report/20909/